


**IN THE CLAIMS:**

1. (Withdrawn) Compounds of formula I :



wherein


$R^1 = H$ , or  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $=CHR^3$ , -  
 $C(O)OR^3$ ,  $-C(O)R^3$ ,  $-CH_2C(O)OR^3$ ,  $-CH_2C(O)NHR^3$ , where  $R^3$  is H or  $C_1$ - $C_{10}$  alkyl, cycloalkyl, or  
alkenyl;

$R^2 = C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;


$R^1 = NHR^4$ , where  $R^4$  is H,  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  
the  $R^4$  group optionally containing a carbonyl group, a carboxyl group, a carboxamide group,  
an alcohol group, or an ether group, the  $R^4$  group further optionally containing one or more  
halogen atoms.

2. (Withdrawn) The compounds of claim 1, wherein  $R^1$  is H, or  $C_1$ - $C_{10}$  alkyl, cycloalkyl,  
alkenyl, aryl, arylalkyl, or alkylaryl, or  $=CH_2$ .
3. (Withdrawn) The compounds of claim 2, wherein  $R^1$  is  $-CH_3$  or  $=CH_2$ .


4. (Withdrawn) The compounds of claim 3, wherein the compound is selected from the group consisting of:



5. (Withdrawn) The compounds of claim 1, wherein  $R^4$  is  $-\text{CH}_2\text{C}(\text{O})\text{OR}^5$  or  $-\text{CH}_2\text{C}(\text{O})\text{NHR}^5$ , where  $R^5$  is H,  $\text{C}_1\text{-C}_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
6. (Withdrawn) The compounds of claim 1, wherein the compound is selected from the group consisting of:



7. (Withdrawn) Compounds of formula II:



II

wherein


$R^6 = H$ , or  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $-C(O)OR^8$ ,  $-C(O)R^8$ ,  $-CH_2C(O)OR^8$ ,  $-CH_2C(O)NHR^8$ , where  $R^8$  is H or  $C_1$ - $C_{10}$  alkyl, cycloalkyl, or alkenyl;

$R^7 = C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

$X^2 = NHR^9$ , where  $R^9$  is H,  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the  $R^9$  group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the  $R^9$  group further optionally containing one or more halogen atoms;

with the proviso that when  $R^6$  is  $-CH_3$ , and  $R^7$  is  $n-C_{13}H_{27}$ ,  $X^2$  is not  $-NHC_2H_5$ .

8. (Withdrawn) The compounds of claim 7, wherein  $R^6$  is  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
9. (Withdrawn) The compounds of claim 8, wherein  $R^6$  is  $-CH_3$ .
10. (Withdrawn) The compounds of claim 7, wherein  $R^9$  is  $-CH_2C(O)OR^{10}$  or  $-CH_2C(O)NHR^{10}$ , where  $R^{10}$  is H,  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
11. (Withdrawn) Compounds of formula IV:



**IV**

wherein

$R^{16} = H$ , or  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $-C(O)OR^{18}$ ,  $-C(O)R^{18}$ ,  $-\text{CH}_2C(O)OR^{18}$ ,  $-\text{CH}_2C(O)NHR^{18}$ , where  $R^{18}$  is  $H$  or  $C_1$ - $C_{10}$  alkyl, cycloalkyl, or alkenyl;

$R^{17} = C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

$X^4 = OR^{19}$ , where  $R^{19}$  is  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the  $R^{19}$  group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the  $R^{19}$  group further optionally containing one or more halogen atoms;

with the proviso that when  $R^{16}$  is  $-\text{CH}_3$  and  $R^{19}$  is  $-\text{CH}_3$ , then  $R^{17}$  is not substituted or unsubstituted phenyl,  $-\text{nC}_3\text{H}_7$ ,  $-\text{nC}_3\text{H}_{11}$ ,  $-\text{nC}_{13}\text{H}_{27}$ , and with the further proviso that when  $R^{16}$  is  $H$  and  $R^{19}$  is  $-\text{CH}_3$ , then  $R^{17}$  is not substituted or unsubstituted phenyl or  $-\text{CH}_3$ , and when  $R^{16}$  is  $H$  and  $R^{19}$  is  $-\text{CH}_2\text{CH}_3$ , then  $R^{17}$  is not  $-\text{iC}_3\text{H}_7$ , or substituted or unsubstituted phenyl.

12. (Withdrawn) The compounds of claim 11, wherein  $R^{16}$  is  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

13. (Withdrawn) The compounds of claim 12, wherein  $R^{16}$  is  $-\text{CH}_3$ .

14. (Withdrawn) The compounds of claim 11, wherein  $R^{19}$  is  $-\text{CH}_2C(O)OR^{20}$  or  $-\text{CH}_2C(O)NHR^{20}$ , where  $R^{20}$  is  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

15. (Currently Amended) Compounds of formula V:



**V**

wherein

$R^{21} = \text{C}_2\text{-C}_{20}\text{ alkyl}$ , cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $=\text{CHR}^{23}$ ,  $-\text{C}(\text{O})\text{OR}^{23}$ ,  $-\text{C}(\text{O})\text{R}^{23}$ ,  $-\text{CH}_2\text{C}(\text{O})\text{OR}^{23}$ ,  $-\text{CH}_2\text{C}(\text{O})\text{NHR}^{23}$ , where  $R^{23}$  is H or  $\text{C}_1\text{-C}_{10}$  alkyl, cycloalkyl, or alkenyl, except when  $R^{21}$  is  $=\text{CHR}^{23}$ ,  $R^{23}$  is not H;


$R^{22} = \text{C}_2\text{-C}_{20}$  alkyl, cycloalkyl, alkenyl, ~~aryl~~, arylalkyl, or alkylaryl;

with the proviso that when  $R^{21}$  is  $-\text{COOH}$ , then  $R^{22}$  is not  $-\text{CH}_3$ ,  $-\text{nC}_5\text{H}_{11}$ , or  $\text{C}_{13}\text{H}_{27}$  and with the further proviso that when  $R^{21}$  is  $-\text{CH}_2\text{COOH}$ , then  $R^{22}$  is not  $-\text{CH}_2\text{CH}_3$ , or  $-\text{iC}_5\text{H}_{11}$ .

16. (Currently Amended) The compounds of claim 15, wherein  $R^{21}$  is  ~~$\text{C}_2\text{-C}_{20}$  alkyl~~, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

17. (Cancelled)

18. (Withdrawn) Compounds of formula VI:



**VI**

wherein:


$R^{24} = C_2-C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $-C(O)OR^{26}$ ,  $-C(O)R^{26}$ ,  $-CH_2C(O)OR^{26}$ ,  $-CH_2C(O)NHR^{26}$ , where  $R^{26}$  is H or  $C_1-C_{10}$  alkyl, cycloalkyl, or alkenyl;

$R^{25} = C_1-C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl;

with the proviso that when  $R^{24}$  is  $-COOH$ , then  $R^{25}$  is not  $-CH_3$ ,  $-nC_5H_{11}$ , or  $C_{13}H_{27}$ , and with the further proviso that when  $R^{24}$  is  $-CH_2COOH$ , then  $R^{25}$  is not  $-CH_3$ ,  $-CH_2CH_3$ , or  $-iC_5H_{11}$ .

19. (Withdrawn) The compounds of claim 18, wherein  $R^{24}$  is  $C_2-C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

20. (Currently Amended) Compounds of formula VII:




wherein

$R^{27} = C_{4-20}$  alkyl,  $C_{4-20}$  alkyl,  $C_{16}-C_{20}$  alkyl.

21 – 22. (Cancelled)

23. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IX:



**IX**

$R^{29} = \text{H, or } C_1\text{-}C_{20} \text{ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, } =\text{CHR}^{31},$

$-\text{C}(\text{O})\text{OR}^{31}, -\text{C}(\text{O})\text{R}^{31}, -\text{CH}_2\text{C}(\text{O})\text{OR}^{31}, -\text{CH}_2\text{C}(\text{O})\text{NHR}^{31},$  where  $R^{31}$  is H or  $C_1\text{-}C_{10}$  alkyl, cycloalkyl, or alkenyl;

$R^{30} = C_1\text{-}C_{20} \text{ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl};$


$X^5 = -\text{OR}^{32}, \text{ or } -\text{NHR}^{32},$  where  $R^{32}$  is H,  $C_1\text{-}C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the  $R^{32}$  group optionally containing a carbonyl group, a carboxyl group, a carboxamide group, an alcohol group, or an ether group, the  $R^{32}$  group further optionally containing one or more halogen atoms;

with the proviso that when  $R^{29}$  is  $=\text{CH}_2$ , then  $X^5$  is not OH.

24. (Withdrawn) The pharmaceutical compositions of claim 23, wherein  $R^{29}$  is  $C_1\text{-}C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or  $=\text{CH}_2$ .

25. (Withdrawn) The pharmaceutical compositions of claim 24, wherein  $R^{29}$  is  $-\text{CH}_3$  or  $=\text{CH}_2$ .

26. (Withdrawn) The pharmaceutical compositions of claim 23, wherein  $R^{32}$  is  $-\text{CH}_2\text{C}(\text{O})\text{OR}^{33}$  or  $-\text{CH}_2\text{C}(\text{O})\text{NHR}^{33}$ , where  $R^{33}$  is  $\text{C}_1\text{-C}_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.
27. (Withdrawn) The pharmaceutical compositions of claim 23, where  $R^{29}$  is  $-\text{C}_6\text{H}_{13}$  or  $-\text{C}_8\text{H}_{17}$ .
28. (Withdrawn) The pharmaceutical compositions of claim 23, wherein the compound is selected from the group consisting of:



29. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 1.
30. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 7.
31. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 11.




32. (Original) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 15.

33. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 18.

34. (Original) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 20.

35. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 22.

36. (Withdrawn) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to Formula III:



**III**

wherein

$R^{11} = \text{H, or } C_1\text{-}C_{20} \text{ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, } =\text{CHR}^{13},$   
 $-\text{C}(\text{O})\text{OR}^{13}, -\text{C}(\text{O})\text{R}^{13}, -\text{CH}_2\text{C}(\text{O})\text{OR}^{13}, -\text{CH}_2\text{C}(\text{O})\text{NHR}^{13},$  where  $R^{13}$  is H or  $C_1\text{-}C_{10}$  alkyl,  
cycloalkyl, or alkenyl;

$R^{12} = C_1\text{-}C_{20} \text{ alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl ;}$

$X^3 = OR^{14}$ , where  $R^{14}$  is  $C_1$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the  $R^{14}$  group optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the  $R^{14}$  group further optionally containing one or more halogen atoms.

37. (Withdrawn) The pharmaceutical formulation of claim 36, wherein  $R^{11}$  is  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or  $=CH_2$ .

38. (Withdrawn) The pharmaceutical formulation of claim 37, wherein  $R^{11}$  is  $-CH_3$  or  $=CH_2$ .


39. (Withdrawn) The pharmaceutical formulation of claim 36, wherein  $R^{14}$  is  $-CH_2C(O)OR^{15}$  or  $CH_2C(O)NHR^{15}$ , where  $R^{15}$  is  $C_1$ - $C_{10}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

40. (Withdrawn) A method of inducing weight loss in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


41. (Withdrawn) The method of claim 40, wherein the subject is a human.

42. (Withdrawn) The method of claim 40, wherein the subject is an animal.

43. (Withdrawn) The method of claim 41, wherein the pharmaceutical composition comprises a compound selected from the group consisting of



44. (Withdrawn) The method of claim 42, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:




45. (Withdrawn) A method of inhibiting growth of cancer cells in an animal or human subject, comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.






46. (Withdrawn) The method of claim 45, wherein the subject is a human.

47. (Withdrawn) The method of claim 45, wherein the subject is an animal.

48. (Withdrawn) The method of claim 46, wherein the pharmaceutical composition comprises a compound selected from the group consisting of



49. (Withdrawn) The method of claim 47, wherein the pharmaceutical composition comprises a compound selected from the group consisting of:


(a)	(a1)	(a2)	(a3)
			
(a')			
			

50. (Withdrawn) A method of stimulating the activity of CPT-1 in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.


51. (Withdrawn) The method of claim 50, wherein the subject is a human.

52. (Withdrawn) The method of claim 50, wherein the subject is an animal.


53. (Withdrawn) The method of claim 51, wherein the compound is:













54. (Withdrawn) The method of claim 52, wherein the compound is:



55. (Withdrawn) A method of inhibiting the activity of neuropeptide-Y in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.
56. (Withdrawn) The method of claim 55, wherein the subject is a human.
57. (Withdrawn) The method of claim 55, wherein the subject is an animal.
58. (Withdrawn) A method of inhibiting fatty acid synthase activity in an animal or human subject comprising administering an effective amount of a pharmaceutical composition according to claim 23 to said subject.
59. (Withdrawn) The method of claim 58, wherein the subject is a human.
60. (Withdrawn) The method of claim 58, wherein the subject is an animal.
61. (Withdrawn) The method of claim 59, wherein the compound is selected from the group consisting of:




62. (Withdrawn) The method of claim 60, wherein the compound is selected from the group consisting of:

 $\text{H}_3\text{C}(\text{H}_2\text{C})_7$	 $\text{H}_3\text{C}(\text{H}_2\text{C})_7$	 $\text{H}_3\text{C}(\text{H}_2\text{C})_7$	 $\text{H}_3\text{C}(\text{H}_2\text{C})_7$
 (*) $\text{H}_3\text{C}(\text{H}_2\text{C})_7$	 (*) $\text{H}_3\text{C}(\text{H}_2\text{C})_7$	 (*) $\text{H}_3\text{C}(\text{H}_2\text{C})_7$	 (*) $\text{H}_3\text{C}(\text{H}_2\text{C})_7$
 $\text{H}_3\text{C}(\text{H}_2\text{C})_7$ , and	 (*) $\text{H}_3\text{C}(\text{H}_2\text{C})_7$		


63. (Withdrawn) A method of inhibiting growth of invasive microbial cells in an animal or human subject comprising the administration of an effective amount of a pharmaceutical composition according to claim 23 to said subject.

64 - 65. (Cancelled)

66. (Withdrawn) The method of claim 64, wherein the compound is selected from the group consisting of:



67. (Withdrawn) The method of claim 65, wherein the compound is selected from the group consisting of:



68. (Not Entered)

69. (Currently Amended) Compounds according to claim 15, wherein


$R^{21}$  = cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl,  $=CHR^{23}$ ,  $-C(O)OR^{23}$ ,  $-C(O)R^{23}$ ,  $-CH_2C(O)OR^{23}$ ,  $-CH_2C(O)NHR^{23}$ , where  $R^{23}$  is H or C<sub>1</sub>-C<sub>10</sub> alkyl, cycloalkyl, or alkenyl, except when  $R^{21}$  is  $=CHR^{23}$ ,  $R^{23}$  is not H ;

$R^{22}$  = C<sub>1</sub>-C<sub>20</sub> alkyl, cycloalkyl, alkenyl, ~~aryl~~, arylalkyl, or alkylaryl;

with the proviso that when  $R^{21}$  is  $-COOH$ , then  $R^{22}$  is not  $-CH_3$ ,  $-C_{13}H_{27}$  or  $C_{13}H_{27}$  and with the further proviso that when  $R^{21}$  is  $-CH_2COOH$ , then  $R^{22}$  is not  $-CH_2CH_3$ , or  $-iC_5H_{11}$ .

70. (Previously Presented) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 69.

71. (Previously Presented) Compounds of formula X:



wherein

$R^{42}$  =  $C_2$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

72. (Previously Presented) A pharmaceutical composition comprising a pharmaceutical diluent and a compound according to claim 71.

73. (New) A method of inhibiting the activity of fatty acid synthase in a cell comprising administering to the cell an effective amount of a pharmaceutical composition comprising a pharmaceutical diluent and one or more compounds of formula V:



**V**

wherein

$R^{21}$  =  $C_2$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, =CHR<sup>23</sup>, -C(O)OR<sup>23</sup>

-C(O)R<sup>23</sup>, -CH<sub>2</sub>C(O)OR<sup>23</sup>, -CH<sub>2</sub>C(O)NHR<sup>23</sup>, where R<sup>23</sup> is H or  $C_1$ - $C_{10}$  alkyl, cycloalkyl, or alkenyl; and

$R^{22}$  =  $C_2$ - $C_{20}$  alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.